MADIT II Trial

Summary: Evaluated implantable cardioverter defibrillators (ICDs) versus none in patients with a myocardial infarction with ejection fractions < 30%. The primary endpoint of all-cause mortality was significantly reduced.

Original Publication:

N Engl J Med. Mar 2002;21;346(12):877-83.

Eponym: Multicenter Automatic Defibrillator Implantation Trial II